Journal article
Stated Preferences for Attributes of a CYP2C19 Pharmacogenetic Test Among the General Population Presented with a Hypothetical Acute Coronary Syndrome Scenario
Abstract
BACKGROUND: Pharmacogenetic (PGx) testing identifies pharmacotherapeutic risks to permit personalized therapy. Identifying the genetic profile of patients with acute coronary syndrome (ACS) who are considered for therapy with clopidogrel (P2Y12 receptor blockers) and acetylsalicylic acid (ASA) contributes to the treatment paradigm. Patient preferences would inform a collaborative framework and by extension inform healthcare policy formulation.
Authors
Bereza BG; Coyle D; So DY; Kadziola Z; Wells G; Grootendorst P; Papadimitropoulos EA
Journal
ClinicoEconomics and Outcomes Research, Vol. 12, No. 0, pp. 167–175
Publisher
Taylor & Francis
Publication Date
March 19, 2020
DOI
10.2147/ceor.s234298
ISSN
1178-6981